Agendia
Precision Oncology
- Website
- agendia.com · all feeds from this site
- Feed URL
https://agendia.com/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
AI-Based Digital MammaPrint Assay Predicts Recurrence Risk and Survival in Early-Stage Breast Cancer
Dr Laura van 't Veer, PhD, talks to eCancer at ESMO 2026 about the development and validation of an AI-based digital pathology assay designed to predict breast cancer recurrence risk using routine tissue samples. The model was trained on 70,000 whole-slide images to reproduce…
-
AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer
Publication: ESMO 2026 Authors: L. Van't Veer; Laboratory Medicine, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, United States of America Title: AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in…
-
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach
The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER cohort of 372 early-stage breast cancer patients with a median follow-up of 10.3 years IRVINE, Calif., and AMSTERDAM — October 25, 2026 — Agendia, Inc., a…
-
70-Gene Signature Provides Prognostic Value Beyond Ki67 in HR+HER2– Early Breast Cancer (EBC)
Publication: ESMO 2026 Authors: Michael Gnant, Mehran Habibi, Adam Brufsky, Laila Samiian, Sasha Davis, Eduardo Dias, Virginia Borges, Kent Hoskins, VK Gadi, Cynthia Osborne, Rakhshanda Layeequr-Rahman, Alfredo Santillan, Harshini Ramaswamy, Raquel Weber, Andrea Menicucci,…
-
Impact of Germline BRCA1 and BRCA2 Mutations on 70-Gene Signature Risk for patients enrolled in the FLEX Study
Publication: ESMO 2026 Authors: Amir Sonnenblick (first and presenting), Mehran Habibi, Laura Lee, Eduardo Dias, Alfredo Santillan, Beth Sieling, Nicole Sookhan, Laila Samiian, Sasha Strain, Jaime Alberty, Massimo Cristofanelli, Priscilla McAuliffe, Samuel Benjamin, Sahra Uygun,…
-
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026
Podium presentation by Co-Founder and Chief Research Officer Laura van ’t Veer introduces an AI-driven approach to MammaPrint Two additional poster presentations from the FLEX Study IRVINE, Calif., and AMSTERDAM, NETHERLANDS, September 25, 2026. Agendia, Inc., a leader in…
-
How One Test Changed The Course of My Breast Cancer Journey
Not every woman with early-stage breast cancer needs chemotherapy. Genomic tests like MammaPrint are helping doctors determine who does. When I was diagnosed with Stage IIA breast cancer in late 2017, I thought the hardest decisions had already been made for me. There is a…
-
Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients
Agendia’s landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care IRVINE, Calif, and AMSTERDAM — Sept 24, 2026 — Agendia®, Inc., a leader in precision oncology for breast cancer, today announced…
-
What Does a MammaPrint High Risk Result Mean?
MammaPrint evaluates the expression of 70 genes associated with breast cancer behavior and recurrence risk. MammaPrint High Risk tumors are more likely to benefit from chemotherapy than Low Risk tumors. The post What Does a MammaPrint High Risk Result Mean? appeared first on…
-
Cancer Diagnostics Are Expanding As New Approaches Provide a Broader View of Tumor Biology and Disease Progression
For years, a cancer diagnosis often came down to one test, one gene, one mutation. Today, clinical laboratories are adopting broader approaches—including whole-genome sequencing, functional RNA profiling, liquid biopsy, and multi-omic testing—that provide more comprehensive…